The prevalence of diabetes among Americans is rising at an alarming pace, with one-third of individuals with the condition requiring daily insulin. Unfortunately, limited healthcare coverage and high deductibles have resulted in financial strain for patients and their families. As a result, some patients are foregoing necessary insulin due to high out-of-pocket costs, resulting in over a million additional hospitalizations annually.
In early 2023, Eli Lilly pledged to limit the cost of insulin to $35 or less, regardless of the patient’s insurance status, thereby ensuring that nobody is deprived of the necessary insulin. Prior to this decision, advocacy groups had been tirelessly campaigning for this change. The Affordable Insulin Project is one such initiative. In 2020, Eli Lilly partnered with the Diabetes Patient Advocacy Coalition (DPAC) and enlisted Stark / Raving to launch a joint pilot campaign aimed at educating and empowering patients on ways to better advocate for reducing the out-of-pocket costs of insulin.